Quantcast

Latest Soft tissue sarcoma Stories

2008-10-16 12:00:05

Ziopharm Oncology, a biopharmaceutical company, has announced that the European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion regarding the company's application for orphan medicinal product designation for palifosfamide in the treatment of soft tissue sarcoma. Palifosfamide, the active moiety of ifosfamide (IFOS), is a bi-functional alkylator that causes irreparable inter-strand DNA cross-linking, resulting in cell death. Palifosfamide is equal to...

2008-10-15 09:00:47

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion regarding ZIOPHARM's application for orphan medicinal product designation for palifosfamide in the treatment of soft tissue sarcoma (STS). In the European Union (EU), products targeted to treat life-threatening or very serious conditions that affect fewer than five in 10,000 people are eligible for orphan...

2008-09-23 09:01:09

SALT LAKE CITY, Sept. 23, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corp. (Nasdaq:BSDM) announced today that the addition of hyperthermia to chemotherapy was recommended as standard therapy for soft tissue sarcoma by the European Society for Medical Oncology (ESMO), the leading European professional medical oncology organization comprising a network of more than 5,000 oncology professionals in over 100 countries. The use of hyperthermia as standard treatment for soft tissue sarcomas was debated...

2008-09-16 09:00:15

REDWOOD CITY, Calif., Sept. 16, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLDD), today announced that it has initiated a Phase 1/2 clinical trial of TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia. "The treatment of soft tissue sarcomas continues to be a difficult challenge. New therapeutic and novel agents are required to improve the...

2008-09-15 09:00:57

SALT LAKE CITY, Sept. 15, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corporation (Nasdaq:BSDM) today reported that a new article in Current Option in Oncology (see 2008, 20:pages 438-443) highlights strong success from the use of the BSD-2000 manufactured by BSD Medical Corporation, in treating patients with high risk soft tissue sarcomas. Central to the article's review of sarcoma studies using the BSD-2000 is the results of a phase III study involving 341 randomized patients with high risk soft...

2008-09-04 12:00:33

An Italian-led international study has identified a tumor suppressor gene as the first independent prognostic biomarker in cases of soft tissue sarcoma. The scientists said they examined specimens taken from 41 patients with soft tissue cancer. In a subset of 31 cases of non-metastatic cancers, they found a direct relationship between gene pRb2/p130 expression and the clinical outcome of patients. "We found that pRb2/p130 expression was lost or decreased and significantly correlated with...

2008-08-29 03:00:19

By Chotel, F Unnithan, A; Chandrasekar, C R; Parot, R; Jeys, L; Grimer, R J We have analysed the pattern of symptoms in patients presenting with synovial sarcoma to identify factors which led to long delays in diagnosis. In 35 children, the early symptoms and the results of clinical and radiological investigation were reviewed, along with the presumed diagnoses. The duration of symptoms was separated into patient delay and doctor delay. Only half of the patients had one or more of the four...

2008-07-31 09:01:26

SALT LAKE CITY, July 31, 2008 (PRIME NEWSWIRE) -- BSD Medical Corporation (Nasdaq:BSDM) today announced that the company's most advanced cancer treatment system, the BSD-2000/3D/MR, has been adapted to treat children with cancer, as well as adults. To accommodate the treatment of children, BSD Medical has developed sophisticated treatment applicators that are specifically sized for small and medium-sized children, and that are capable of delivering pediatric cancer therapy during simultaneous...

2008-07-08 09:01:11

ImClone Systems has announced that a Phase II clinical trial of IMC-A12, the company's fully human, IgG1 anti-insulin-like growth factor-1 receptor monoclonal antibody, in adolescents and adult patients with several types of soft tissue sarcoma has opened for patient enrollment. This multinational Phase II study will evaluate the efficacy of IMC-A12 in adult and adolescent patients with several types of previously treated, advanced or metastatic soft tissue sarcoma, which were selected...

2008-07-07 09:01:02

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that a Phase 2 clinical trial of IMC-A12, ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in adolescents and adult patients with several types of soft tissue sarcoma has opened for patient enrollment. "This Phase 2 study of IMC-A12 builds on a biological rationale that suggests that the...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin